PCRX

Pacira BiosciencesB

Nasdaq / Pharmaceuticals, Biotechnology & Life Sciences

At close

2026-07-18

Current thesis

The post-earnings bull case is that Pacira now has synchronized revenue growth across EXPAREL, ZILRETTA, and iovera, reiterated full-year guidance, and several 2026 data catalysts that could expand the commercial footprint or validate the HCAd platform. Primary filings also show $202.2 million of cash and investments and management states near-term liquidity is adequate [#10-Q-2026-04-30].

Posture

Constructive

Lead driver

Value

What changed

Value remains the lead driver in the composite, 7D delta -0.2.

What can break

At March 31, 2026, Pacira had about $367.7 million of debt, including 2029 converts and a revolving credit facility, while also spending $50.0 million on buybacks in Q1 [#10-Q-2026-04-30].

Momentum

Value

Sentiment

Setup hits (3d)

— · Net —

AI TargetsBase $28.00 · Bull $34.00 · Bear $17.00

Data freshness

Prices

As of 2026-07-18

Fundamentals

As of 2026-07-17 • Vendor: Data Vendor v1

Scores

As of 2026-07-18 • Model: HYBRID_IC_RP

AI Memo

As of 2026-05-03 • Model: RankAlpha Sentiment Codex

Investment thesis

As of 2026-07-18

Supporting evidence

What

Grade B · Constructive

Confidence Medium · Net —

Target $29.67

Why

Momentum43 · Δ7d +21.4

Value69 · Δ7d -0.2

Sentiment48 · Δ7d -4.2

So what

Strength-led posture. Favor watchlist adds and disciplined entries.

Setup hits not loaded

Load setup hits to see net bias and recent triggers.

Load setup hits

Lead driver: Value · See fundamentals

Momentum

26% active weight

Current posture

7d trendFlat

Δ7d

+21.4

Δ21d

+37.3

Value

39% active weight

Current posture

7d trendFlat

Δ7d

-0.2

Δ21d

-0.0

Sentiment

34% active weight

Current posture

7d trendSoftening

Δ7d

-4.2

Δ21d

-3.2

Why this grade

Composite grade B. Momentum 43.1 / Value 68.9 / Sentiment 48.3

Fundamentals (TTM)

As of 2026-07-17

Market Cap

$1.01B

Beta

0.25

Shares Out

39.34M

P/E (TTM)

53.8

P/S (TTM)

1.51

P/FCF (TTM)

8.69

Rev YoY

+5.0%

EPS YoY

-31.0%

Gross Margin

+71.5%

Op Margin

+4.1%

Net Debt

$179.78M

Current Ratio

4.73

As of 2026-07-18 • Updated nightlySource: Internal modelMethodology